secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2023-09-28T23:59:59+00:00
Accession:  0001601485-23-000060
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio reports ELI-002 Phase 1 data: median RFS not reached vs 3.9 months, HR=0.14
--------------------------------------------------------------------------------

- Median RFS not reached for high T cell responders vs 3.9 months for low (HR=0.14; p=0.013).
- 86% reduction in risk of progression or death in patients with large T cell responses.
- Tumor biomarker reduction/clearance -86.9% vs -1.0% in above vs below median T cell responders (p<0.0017).
- Plan to initiate randomized Phase 2 study of ELI-002 7P in adjuvant PDAC patients early 2024.
- No ≥Grade 3 treatment-related AEs; safety profile supports further development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000060/0001601485-23-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000060/angn-20230927.htm
  HTML page:      https://secwatch.observer/filing/0001601485-23-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer